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Mucopolysaccharidosis Type IIIB (MPSIIIB) is a paediatric, autosomal recessive Lysosomal Storage 
Disease (LSD) caused by deficiency of α-N-acetylglucosaminidase (NAGLU), an enzyme in the heparan 
sulfate (HS) degradation pathway. Absence of NAGLU leads to the accumulation of partially degraded 
HS glycosaminoglycan in cell lysosomes, giving rise to cellular dysfunction with devastating clinical 
consequences. Individuals affected by this fatal disease exhibit severe central nervous system 
degeneration with progressive cognitive impairment and behavioural problems, alongside more 
attenuated somatic symptoms. There are currently no effective treatments available. Enzyme 
replacement therapy with recombinant NAGLU enzyme is ineffective for MPSIIIB since enzyme cannot 
cross the blood brain barrier (BBB) to where it is needed. Modified recombinant NAGLU enzymes that 
utilise the insulin growth factor II (IGFII) peptide to facilitate improved uptake across the BBB are 
currently in development. Haematopoietic stem cell gene therapy (HSCGT) is a promising therapeutic 
strategy that can circumvent the BBB via monocyte trafficking and engraftment in the brain, allowing 
delivery of enzyme by cross correction. We have developed a novel stem cell gene therapy approach 
to investigate the therapeutic potential of HSCGT for MPSIIIB. We designed two lentiviral vectors 
expressing therapeutic enzyme; the first vector expressing codon optimised NAGLU, and the second 
expressing a NAGLU.IGFII fusion to aid cellular uptake, both driven by the myeloid specific promoter 
CD11b and compared these in autologous MPSIIIB transplants against a normal WT bone marrow 
transplant. Here we present for the first time neurological correction of MPSIIIB mice by HSCGT. We 
observed correction of the MPSIIIB behavioural phenotype in treated mice to wild-type levels with 
normalisation of path length, average speed, frequency entering the centre and duration of speed 
>100mm/s in open field tests. In addition, we observed a significant correction of astrogliosis and 
lysosomal compartment size in the brains of CD11b. NAGLU LV treated mice with an accompanied 
normalisation of inflammatory cytokines TNFα, IL1B and IL1RN. Furthermore, NAGLU enzyme activity 
was substantially increased in the brain. Interestingly, WT transplant alone was able to mediate a 
partial brain correction, although levels of inflammation and lysosomal storage remain high. 
